Oncoceutics, Inc. logo

Oncoceutics, Inc.

Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class compounds that selectively target G protein-coupled receptors for oncology. The first lead compound to result from this program is ONC201, an orally active DRD2 small molecule antagonist that is well-tolerated and effective against advanced cancers.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://oncoceutics.com
Founded2009
Disease Focus
Development Stage
STOCK CODENon Listed
Address
3624 Market Street University City Science Center, Suite 5E, PA 19104
Philadelphia
United States
Email
Contact Number
+1 717-531-8520

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/oncoceutics-inc-” connections=”true” suffix=””]